Under the Department of Transportation (DOT) rule 49 CFR part 40, drug testing regulations mandate urine testing under a five-panel test.
Effective October 1st, 2017 the DOT drug testing panel is set to expand to include four new prescription medications (Hydrocodone, Hydromorphone, Oxycodone, Oxymorphone).
The expanded drug testing panel will still be called a five-panel as the expansion will be within the opioids category. Previously under opioids, this panel only tested for Codeine, Morphine and 6-MAM (heroin). Now, four more Schedule II drugs are being added to this category.
The DOT will also rename its existing opiates category in Sec. 40.85 from “opiates” to “opioids”.
According to CDC, in 2012 approximately 260 million prescriptions were written for these opioids. The fear of potential abuse of these drugs in the workplace and its impact on safety is the driving force for these changes.
You can read more about it here.
At ARCpoint Labs of Southboro-Framingham, we help companies remain DOT compliant. Call us today at (508) 834-3760 to speak to our DOT specialist!